BioAge Labs (NASDAQ:BIOA) Hits New 12-Month High – Here’s Why

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $16.85 and last traded at $16.0640, with a volume of 317585 shares changing hands. The stock had previously closed at $14.03.

Wall Street Analysts Forecast Growth

BIOA has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

The company has a market cap of $821.68 million, a P/E ratio of -15.08 and a beta of 1.38. The business’s 50 day moving average price is $11.68 and its 200-day moving average price is $7.43.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Insider Activity at BioAge Labs

In other news, insider Paul D. Rubin sold 18,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $12.00, for a total transaction of $216,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. acquired a new position in BioAge Labs in the second quarter valued at about $206,000. Public Employees Retirement System of Ohio acquired a new stake in BioAge Labs during the 2nd quarter worth approximately $57,000. Police & Firemen s Retirement System of New Jersey bought a new stake in BioAge Labs in the 2nd quarter valued at $27,000. Stonepine Capital Management LLC lifted its holdings in shares of BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.